Citius Oncology, Inc.

CTOR Nasdaq SEC CIK 1851484
Follow Citius Oncology Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $1.5M
Net income −$8.9M −66.2% vs same quarter last year
EPS, diluted −$0.08 +0% vs same quarter last year
Operating cash flow −$2.7M
Revenue by quarter
$3.9M
$1.7M
$1.5M
Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income5 fiscal years
−$30M−$20M−$10M$0FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$24.8M
FY24−$21.1M
FY23−$12.7M
FY22-
FY21-